3yr
Daridorexant in Insomnia Disorder: A Profile of Its Use - CNS Drugs
Source : https://link.springer.com/article/10.1007/s40263-023-00987-9
Daridorexant (Quviviq™) is a useful option for the treatment of insomnia disorder, which has shown efficacy in younger and older adults. It antagonises the orexin receptors, thereby reducing the wake drive. Daridorexant is the first dual orexin receptor antagonist to be approved for the treatment of chronic insomnia in the EU and has been approved for insomnia in the USA.
Conclusions: The efficacy of daridorexant was maintained during a 12-month extension trial, with no new safety or tolerability concerns.
• Source: CNS Drugs
• Conclusions/Relevance: “Daridorexant (Quviviq) is a useful option for the treatment of insomnia disorder, which has shown efficacy in younger and older adults. It antagonises the orexin receptors, thereby reducing the wake drive. Daridorexant is the first dual orexin receptor antagonist to be approved for the treatment of chronic insomnia in the EU and has been approved for insomnia in the USA.”
• Daridorexant improves objective latency to persistent sleep, objective waketime following sleep onset, subjective total sleep time, and subjective daytime function (at 50 mg dose), per phase 3 clinical trial results.
• The drug is well tolerated, with falls occurring at a similar or lower rate than placebo. AEs such as fatigue and dizziness are mild and not dependent on dose.
• Daridorexant’s efficacy was sustained during a 12-month safety trial, with no new safety signals.